Traws pharma, inc. TRAW.US Overview
TRAW AI Analysis & Strategy
Analysis Conclusion
With insufficient quarterly financial data released by the company, we're unable to provide a rating.
TRAW Current Performance
-0.60%
Traws pharma, inc.
0.61%
Avg of Sector
-0.03%
S&P500
TRAW Key Information
TRAW Financial Forecast
Unit : USD
TRAW Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | 2.09 | 134.8% | -126% | 57K | 1.8% | -5% | -53,432.1% |
| 2024Q3 | 95.66 | 41,691.3% | -1,101.7% | 56K | -1.8% | -6.7% | -14,868.4% |
| 2024Q2 | -8.81 | -4,248.9% | 41% | 57K | 0% | -5% | -216,040.4% |
| 2024Q1 | -121.75 | -44,089.2% | 1,848% | 57K | 1.8% | -5% | -8,898.2% |
| 2023Q4 | -6 | -2,216.5% | 0% | 56K | 0% | -6.7% | -7,471.4% |
TRAW Profile
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.